Skip to main navigation
Skip to search
Skip to main content
The University of Brighton Home
Home
Profiles
Research units
Equipment
Projects
Research output
Activities
Student theses
Search by expertise, name or affiliation
Emerging drugs for renal failure
P.K. Chatterjee
, C. Thiemermann
University of Brighton
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging drugs for renal failure'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Renal Failure
33%
Angiotensin-converting Enzyme Inhibitor (ACEi)
16%
Atrial Natriuretic Peptide
16%
Beneficial Effects
16%
Calcitriol
16%
Chronic Kidney Disease
83%
Clinical Setting
16%
Dialysis
16%
Emerging Drugs
100%
End-stage Renal Disease
33%
End-stage Renal Failure
50%
Erythropoietin
16%
Essential Function
16%
Expert Team
16%
Kidney
16%
Low-dose Dopamine
16%
Pharmacological Intervention
16%
Rapid Onset
16%
Renal Failure
100%
Renal Inflammation
16%
Renal Replacement Therapy
50%
Renal Transplantation
16%
Risk Factors
16%
Specialized Units
16%
Statins
16%
Sudden Onset
16%
Teamwork
16%
Medicine and Dentistry
ACE Inhibitor
16%
Acute Kidney Injury
33%
Atrial Natriuretic Factor
16%
Calcitriol
16%
Chronic Kidney Disease
83%
End Stage Renal Disease
83%
Erythropoietin
16%
Kidney Transplantation
16%
Low Drug Dose
16%
Nephritic Syndrome
16%
Renal Failure
100%
Renal Replacement Therapy
50%
Statin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
33%
Atrial Natriuretic Factor
16%
Calcitriol
16%
Chronic Kidney Failure
83%
Dipeptidyl Carboxypeptidase Inhibitor
16%
End Stage Renal Disease
83%
Erythropoietin
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Kidney Failure
100%
Nephritis
16%
Replacement Therapy
50%